Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 Current Ratio is 4.79 as of Mar. 2026, which is 102% above its 10-year median of 2.37. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 84.43% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Invicta Diagnostic's current ratio for the quarter that ended in Mar. 2026 was 4.79.
Invicta Diagnostic has a current ratio of 4.79. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Invicta Diagnostic's Current Ratio or its related term are showing as below:
NSE:INVICTA'
s Current Ratio Range Over the Past 10 Years
Min: 1.62 Med: 2.37 Max: 4.79
Current: 4.79
During the past 3 years, Invicta Diagnostic's highest Current Ratio was 4.79. The lowest was 1.62. And the median was 2.37.
NSE:INVICTA's Current Ratio is ranked better than 84.43% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs NSE:INVICTA: 4.79
Invicta Diagnostic (NSE:INVICTA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Invicta Diagnostic Current Ratio Related Terms
Invicta Diagnostic Current Ratio Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic Current Ratio Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
Current Ratio
1.62
2.37
4.79
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
Current Ratio
1.62
2.37
1.73
4.79
NSE:INVICTA vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Current Ratio distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a Current Ratio of 4.79 as of Mar. 2026. This is 102% above median its historical median of 2.37. Over the past decade, Invicta Diagnostic's Current Ratio has ranged from 1.62 to 4.79. According to the industry distribution chart, Invicta Diagnostic ranks #33 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 15.6%.
Is Invicta Diagnostic's Current Ratio too high?
Invicta Diagnostic's current Current Ratio of 4.79 is 102% above median its 10-year median of 2.37. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 4.79. The Medical Diagnostics & Research industry median Current Ratio is 2.10. Invicta Diagnostic's value of 4.79 is 128.1% above this industry median. Based on the distribution chart, Invicta Diagnostic ranks #33 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #33 out of 212 companies for Current Ratio. This places Invicta Diagnostic in the top 16% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.10. Invicta Diagnostic's value of 4.79 is 128.1% above this benchmark. Historically, Invicta Diagnostic's own Current Ratio has ranged from 1.62 to 4.79 over the past decade. While the company's 10-year median is 2.37 vs. the industry median of 2.10, Invicta Diagnostic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invicta Diagnostic's current Current Ratio of 4.79 is 128.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current Current Ratio is 4.79, which is 102% above median its own 10-year median of 2.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Current Ratio of 4.79. The current Current Ratio is 4.79, which is 102% above median its 10-year median of 2.37 and 128.1% above the Medical Diagnostics & Research industry median of 2.10. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Current Ratio is 4.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
